查看購物車
  • English
  • Japanese
封面
市場調查報告書
商品編碼
2037539

數位病理市場預測至2034年—按產品類型、類別、部署模式、工作流程、技術、應用、最終用戶和地區分類的全球分析

Digital Pathology Market Forecasts to 2034 - Global Analysis By Product, Type, Deployment Mode, Workflow, Technology, Application, End User, and By Geography
出版日期: | 出版商: Stratistics Market Research Consulting | 英文 | 商品交期: 2-3個工作天內

價格

根據 Stratistics MRC 的數據，預計到 2026 年，全球數位病理市場規模將達到 16 億美元，並在預測期內以 13.7% 的複合年成長率成長，到 2034 年將達到 46 億美元。

數位病理學是一種將傳統玻璃切片轉化為高解析度數位影像的技術，這些影像可以透過電腦顯示器和行動裝置進行檢視、分析和共用。這項革命性技術使病理學家能夠遠端診斷疾病並進行協作，並圖人工智慧 (AI) 演算法來提高準確性和效率。該市場涵蓋數位成像系統、AI 分析平台、雲端儲存解決方案和遠端病理網路，這些技術正在從根本上改變全球醫療保健系統的檢查室工作流程和診斷醫學。

慢性病和癌症患者數量增加

全球癌症和慢性疾病負擔日益加重，對數位病理學提供的更快、更精準的診斷解決方案的需求空前高漲。傳統的顯微鏡診斷耗時費力，且限制了專家間的協作，而數位化工作流程無需運送實體切片即可實現病例的快速共用和第二意見。預計未來十年癌症病例將顯著增加，醫療系統面臨著在保持診斷準確性的同時提升診斷處理能力的巨大壓力。數位病理學透過簡化工作流程、縮短檢測結果返回時間，並使病理學家能夠在不影響診斷品質的前提下處理更多病例，從而應對了這一挑戰，使其在現代檢查室中的應用變得日益重要。

高昂的初始基礎設施和整合成本

實施數位病理需要大量的資金投入，這仍然是一個限制因素，尤其對於小規模的檢查室和醫療機構。建造一套完整的系統需要高解析度玻片掃描器、大規模儲存基礎設備、高效能閱片工作站，以及與現有實驗室資訊系統的整合。此外，從傳統工作流程過渡到數位工作流程需要大量的員工培訓和工作流程的重新設計，這會導致初始硬體購置成本以外的隱性成本。在預算緊張的醫療系統中，尤其是在發展中地區，其他資本投資往往優先於數位病理的採用，這阻礙了市場滲透，儘管全面實施後最終可以獲得長期的營運效益和效率提升。

將人工智慧應用於診斷支持

先進的人工智慧演算法透過擴展病理學家的能力並提高診斷的一致性，正在創造變革性的機會。基於數百萬張帶註釋的病理圖像訓練的機器學習模型能夠檢測到人眼可能忽略的細微細胞異常，標記需要進一步檢查的可疑區域，並以極高的準確度量化生物標記的表達。這些人工智慧助理能夠減少觀察者之間的差異，並幫助優先處理高優先病例，從而使病理學家能夠專注於複雜的診斷挑戰。隨著基於人工智慧的病理診斷工具獲得監管部門核准的增加以及保險報銷機制的建立，將智慧演算法整合到數位病理工作流程中將加速其應用，並將市場拓展到先前服務不足的臨床應用領域。

監管和資料隱私挑戰

醫療設備核准和病患資料保護的嚴格監管要求，對數位病理市場的擴張構成重大障礙。病理影像包含敏感的病患訊息，而基於雲端的儲存解決方案必須符合不同司法管轄區的醫療隱私法規，這對國際營運的供應商來說是一項複雜的挑戰。基於人工智慧的診斷工具的核准流程需要大量的臨床檢驗，這既耗時又昂貴。此外，資料所有權、網路安全風險以及與自動化診斷提案相關的法律責任等問題，也令醫療服務提供者猶豫不決。這些監管障礙可能會減緩創新週期，增加合規成本，並限制市場成長。

新冠疫情的影響：

新冠疫情大大加速了數位病理學的普及，醫療系統在努力維持診斷服務的同時，力求最大限度地減少人際接觸，並支持遠距辦公。封鎖措施導致病理學家無法進入實驗室，迫使他們迅速採用數位化解決方案進行遠端病例審查和遠距醫療。這場危機永久改變了人們的認知，證明遠距數位病理學不僅可行，而且在許多情況下都能作為主要的診斷工具發揮有效作用。儘管供應鏈中斷暫時減緩了硬體的普及，但總體而言，這促成了投資的激增和監管靈活性的提高。疫情過後，結合現場和遠端病理學的混合工作流程已成為標準做法，數位病理學市場正在持續擴張。

在預測期內，人工智慧（AI）領域預計將佔據最大的市場佔有率。

在預測期內，人工智慧 (AI) 領域預計將佔據最大的市場佔有率。這主要歸功於人工智慧演算法在常規病理工作流程中的快速整合，用於診斷支援和品管。人工智慧解決方案正擴大應用於腫瘤檢測、生物標記定量和預後預測，為病理學家提供提高準確性和減少繁瑣的手動測量的工具。領先的診斷實驗室和製藥公司正在大力投資人工智慧平台，以透過自動化分析臨床試驗中的切片檢查檢體來加速藥物研發。不斷擴大的獲得 FDA核准和 CE 認證的人工智慧病理應用庫，以及透過提高效率所展現的投資回報，正在鞏固人工智慧在整個預測期內作為主導技術領域的地位。

在預測期內，「藥物發現與開發」領域預計將呈現最高的複合年成長率。

在預測期內，藥物發現與開發領域預計將呈現最高的成長率，這反映出製藥業在臨床前和臨床研究中對數位病理學的依賴程度日益加深。數位切片分析能夠對組織樣本中的藥物療效和毒性進行定量評估，提供比傳統人工評分更客觀的終點指標。人工智慧演算法可以從大規模臨床試驗資料集中識別細微的治療效果和預測性生物標記物，從而加速候選化合物的篩選並縮短研發週期。隨著製藥公司採用數位化和人工智慧驅動的病理學來提高成功率並減少後期研發失敗帶來的高昂成本，對這些技術的投資正在迅速成長，使其成為數位病理學市場中成長最快的領域。

市佔率最大的地區：

在整個預測期內，北美預計將保持最大的市場佔有率，這得益於其先進的醫療基礎設施、有利的報銷政策以及病理實驗室對數位技術的廣泛應用。領先的數位病理供應商的存在、大學醫院與科技公司之間廣泛的研究合作，以及基於人工智慧的診斷工具早期獲得監管部門的核准，都推動了其市場主導地位。高癌症發生率和大規模參考實驗室的集中分佈正在加速數位技術的應用。美國國立衛生研究院 (NIH) 的政府資助以及私人創業投資投資對數位醫療新創企業的投資，進一步鞏固了該地區的地位，並確保北美在整個預測期內保持其市場主導地位。

複合年成長率最高的地區：

在預測期內，亞太地區預計將呈現最高的複合年成長率，這主要得益於醫療體系的快速現代化、診斷基礎設施投資的增加以及人們對數位病理優勢的日益認可。中國、印度、日本和韓國癌症發病率的上升以及病理學家的短缺，使得對能夠提高效率的技術產生了迫切需求。政府推動醫療數位化和人工智慧應用的舉措，以及醫療旅遊和臨床研究活動的拓展，都在促進市場成長。專注於本地市場的數位病理供應商不斷湧現，提供符合區域需求的、具有成本效益的解決方案，這加速了數位病理技術在都市區醫院和農村偏遠病理網路中的應用，使亞太地區成為成長最快的區域市場。

免費客製化服務：

所有購買此報告的客戶均可享受以下免費自訂選項之一：

  • 企業概況
    • 對其他市場參與者（最多 3 家公司）進行全面分析
    • 對主要公司進行SWOT分析（最多3家公司）
  • 區域細分
    • 應客戶要求，我們提供主要國家的市場估算和預測，以及複合年成長率（註：需進行可行性檢查）。
  • 競爭性標竿分析
    • 根據產品系列、地理覆蓋範圍和策略聯盟對領先公司進行基準分析。

目錄

第1章執行摘要

  • 市場概覽及主要亮點
  • 促進因素、挑戰與機遇
  • 競爭格局概述
  • 戰略洞察與建議

第2章：研究框架

  • 研究目標和範圍
  • 相關人員分析
  • 研究假設和限制
  • 調查方法

第3章 市場動態與趨勢分析

  • 市場定義與結構
  • 主要市場促進因素
  • 市場限制與挑戰
  • 投資成長機會和重點領域
  • 產業威脅與風險評估
  • 技術與創新展望
  • 新興市場/高成長市場
  • 監管和政策環境
  • 新冠疫情的影響及復甦前景

第4章：競爭環境與策略評估

  • 波特五力分析
    • 供應商的議價能力
    • 買方的議價能力
    • 替代品的威脅
    • 新進入者的威脅
    • 競爭公司之間的競爭
  • 主要公司市佔率分析
  • 產品基準評效和效能比較

第5章 全球數位病理市場：依產品分類

  • 掃描器
    • 全幻燈片成像掃描儀
    • 高通量掃描儀
    • 低通量掃描儀
  • 軟體
    • 影像管理軟體
    • 影像分析軟體
  • 儲存和通訊系統
    • 資料安全解決方案
    • 網路與通訊平台

第6章：全球數位病理市場：按類型分類

  • 人類病理學
  • 獸醫病理學

第7章：全球數位病理市場：依部署模式分類

  • 現場
  • 基於雲端的

第8章 全球數位病理市場：依工作流程分類

  • 預分析階段
  • 分析階段
    • 幻燈片數位化
    • 影像處理
  • 分析後階段
    • 影像管理
    • 資料儲存與搜尋
    • 報告撰寫與協作

第9章 全球數位病理市場：依技術分類

  • 月球成像
  • 人工智慧
  • 機器學習
  • 雲端運算
  • 遠距病理診斷

第10章 全球數位病理市場：按應用分類

  • 疾病診斷
  • 藥物發現與開發
  • 遠距醫療
  • 學術研究
  • 培訓和教育

第11章 全球數位病理市場：以最終用戶分類

  • 醫院
  • 診斷檢查室
  • 製藥和生物技術公司
  • 學術研究機構

第12章 全球數位病理市場：按地區分類

  • 北美洲
    • 美國
    • 加拿大
    • 墨西哥
  • 歐洲
    • 英國
    • 德國
    • 法國
    • 義大利
    • 西班牙
    • 荷蘭
    • 比利時
    • 瑞典
    • 瑞士
    • 波蘭
    • 其他歐洲國家
  • 亞太地區
    • 中國
    • 日本
    • 印度
    • 韓國
    • 澳洲
    • 印尼
    • 泰國
    • 馬來西亞
    • 新加坡
    • 越南
    • 其他亞太國家
  • 南美洲
    • 巴西
    • 阿根廷
    • 哥倫比亞
    • 智利
    • 秘魯
    • 其他南美國家
  • 世界其他地區（RoW）
    • 中東
      • 沙烏地阿拉伯
      • 阿拉伯聯合大公國
      • 卡達
      • 以色列
      • 其他中東國家
    • 非洲
      • 南非
      • 埃及
      • 摩洛哥
      • 其他非洲國家

第13章 戰略市場資訊

  • 工業價值網路和供應鏈評估
  • 空白區域和機會地圖
  • 產品演進與市場生命週期分析
  • 通路、經銷商和打入市場策略的評估

第14章 產業趨勢與策略舉措

  • 併購
  • 夥伴關係、聯盟和合資企業
  • 新產品發布和認證
  • 擴大生產能力和投資
  • 其他策略舉措

第15章：公司簡介

  • F. Hoffmann-La Roche Ltd.
  • Danaher Corporation
  • Koninklijke Philips NV
  • Leica Biosystems Nussloch GmbH
  • Hamamatsu Photonics KK
  • 3DHISTECH Ltd.
  • Visiopharm A/S
  • Indica Labs Inc.
  • Paige AI Inc.
  • Proscia Inc.
  • Sectra AB
  • Olympus Corporation
  • Huron Digital Pathology
  • OptraSCAN Inc.
  • XIFIN Inc.
  • Inspirata Inc.
  • Mindpeak GmbH
  • PathAI Inc.
Product Code: SMRC35954

According to Stratistics MRC, the Global Digital Pathology Market is accounted for $1.6 billion in 2026 and is expected to reach $4.6 billion by 2034 growing at a CAGR of 13.7% during the forecast period. Digital pathology involves the conversion of traditional glass slides into high-resolution digital images that can be viewed, analyzed, and shared via computer monitors or mobile devices. This transformative technology enables pathologists to diagnose diseases, collaborate remotely, and apply artificial intelligence algorithms for enhanced accuracy and efficiency. The market encompasses digital imaging systems, AI-powered analytics platforms, cloud-based storage solutions, and telepathology networks that are fundamentally reshaping laboratory workflows and diagnostic medicine across healthcare systems worldwide.

Market Dynamics:

Driver:

Rising prevalence of chronic diseases and cancer cases

The growing global burden of cancer and chronic conditions is creating unprecedented demand for faster, more accurate diagnostic solutions that digital pathology provides. Traditional microscopy-based diagnosis is time-consuming and limits collaboration among specialists, whereas digital workflows enable rapid case sharing and second opinions without physical slide transportation. With cancer cases projected to rise substantially over the coming decade, healthcare systems are under pressure to increase diagnostic throughput while maintaining accuracy. Digital pathology addresses this challenge by streamlining workflows, reducing turnaround times, and enabling pathologists to manage larger caseloads without compromising diagnostic quality, making adoption increasingly essential for modern laboratories.

Restraint:

High initial infrastructure and integration costs

The substantial financial investment required for digital pathology implementation continues to limit adoption, particularly among smaller laboratories and healthcare facilities. Complete systems require high-resolution slide scanners, substantial storage infrastructure, powerful viewing workstations, and integration with existing laboratory information systems. The transition from traditional to digital workflows also demands significant staff training and workflow redesign, adding hidden costs beyond hardware purchases. Budget-constrained healthcare systems, especially in developing regions, often prioritize other capital expenditures over digital pathology adoption, slowing market penetration despite the long-term operational benefits and efficiency gains that these systems eventually deliver once fully implemented.

Opportunity:

Integration of artificial intelligence for diagnostic assistance

Advanced AI algorithms are creating transformative opportunities by augmenting pathologist capabilities and improving diagnostic consistency. Machine learning models trained on millions of annotated pathology images can detect subtle cellular abnormalities that human eyes might miss, flag suspicious regions for closer review, and quantify biomarker expression with remarkable precision. These AI assistants reduce inter-observer variability and help prioritize urgent cases, allowing pathologists to focus on complex diagnostic challenges. As regulatory approvals for AI-based pathology tools increase and reimbursement pathways become established, the integration of intelligent algorithms into digital pathology workflows will accelerate adoption and expand the market into previously underserved clinical applications.

Threat:

Regulatory and data privacy challenges

Stringent regulatory requirements for medical device approval and patient data protection pose significant barriers to digital pathology market expansion. Pathology images contain sensitive patient information, and cloud-based storage solutions must comply with healthcare privacy regulations across different jurisdictions, creating complexity for vendors operating internationally. The approval process for AI-based diagnostic tools requires extensive clinical validation, which is time-consuming and expensive. Additionally, concerns about data ownership, cybersecurity risks, and the legal liability associated with automated diagnostic suggestions create hesitation among healthcare providers. These regulatory hurdles slow innovation cycles and increase compliance costs, potentially limiting market growth.

Covid-19 Impact:

The COVID-19 pandemic dramatically accelerated digital pathology adoption as healthcare systems sought to maintain diagnostic services while minimizing physical contact and enabling remote work. Lockdowns prevented pathologists from accessing laboratory facilities, forcing rapid deployment of digital solutions for remote case review and teleconsultation. The crisis demonstrated that remote digital pathology is not only feasible but also effective for primary diagnosis in many settings, permanently shifting perceptions. Supply chain disruptions temporarily slowed hardware installations, but the overall effect was a surge in investment and regulatory flexibility. Post-pandemic, hybrid workflows combining on-site and remote pathology have become standard practice, permanently expanding the digital pathology market.

The Artificial Intelligence segment is expected to be the largest during the forecast period

The Artificial Intelligence segment is expected to account for the largest market share during the forecast period, driven by the rapid integration of AI algorithms into routine pathology workflows for diagnostic assistance and quality control. AI-powered solutions are increasingly deployed for tumor detection, biomarker quantification, and prognostic predictions, offering pathologists tools that enhance accuracy and reduce tedious manual measurements. Major diagnostic laboratories and pharmaceutical companies are investing heavily in AI platforms to accelerate drug development through automated analysis of clinical trial biopsy samples. The growing library of FDA-approved and CE-marked AI pathology applications, combined with demonstrated return on investment through efficiency gains, positions AI as the dominant technology segment throughout the forecast timeline.

The Drug Discovery and Development segment is expected to have the highest CAGR during the forecast period

Over the forecast period, the Drug Discovery and Development segment is predicted to witness the highest growth rate, reflecting the pharmaceutical industry's increasing reliance on digital pathology for preclinical and clinical research. Digital slide analysis enables quantitative assessment of drug efficacy and toxicity in tissue samples, providing more objective endpoints than traditional manual scoring. AI algorithms can identify subtle treatment effects and predictive biomarkers from large-scale clinical trial datasets, accelerating candidate selection and reducing development timelines. As pharmaceutical companies embrace digital and AI-driven pathology to improve success rates and reduce costly late-stage failures, investment in these technologies is expanding rapidly, making this application the fastest-growing segment in the digital pathology market.

Region with largest share:

During the forecast period, the North America region is expected to hold the largest market share, supported by advanced healthcare infrastructure, favorable reimbursement policies, and strong adoption of digital technologies among pathology practices. The presence of major digital pathology vendors, extensive research collaborations between academic medical centers and technology companies, and early regulatory approvals for AI-based diagnostic tools drive market leadership. High cancer incidence rates and the concentration of large reference laboratories accelerate deployment. Government funding through the National Institutes of Health and private venture capital investment in digital health startups further strengthen the region's position, ensuring North America maintains its dominant market share throughout the forecast period.

Region with highest CAGR:

Over the forecast period, the Asia Pacific region is anticipated to exhibit the highest CAGR, driven by rapidly modernizing healthcare systems, increasing investment in diagnostic infrastructure, and growing awareness of digital pathology benefits. China, India, Japan, and South Korea are witnessing rising cancer rates and pathologist shortages, creating urgent demand for efficiency-enhancing technologies. Government initiatives promoting healthcare digitization and AI adoption, coupled with expanding medical tourism and clinical research activity, fuel market growth. The emergence of regional digital pathology vendors offering cost-effective solutions tailored to local needs accelerates adoption across both urban hospitals and rural telepathology networks, positioning Asia Pacific as the fastest-growing regional market.

Key players in the market

Some of the key players in Digital Pathology Market include F. Hoffmann-La Roche Ltd., Danaher Corporation, Koninklijke Philips N.V., Leica Biosystems Nussloch GmbH, Hamamatsu Photonics K.K., 3DHISTECH Ltd., Visiopharm A/S, Indica Labs Inc., Paige AI Inc., Proscia Inc., Sectra AB, Olympus Corporation, Huron Digital Pathology, OptraSCAN Inc., XIFIN Inc., Inspirata Inc., Mindpeak GmbH, and PathAI Inc.

Key Developments:

In April 2026, PathAI and MedStar Health announced a strategic partnership to deploy the AISight Dx digital pathology platform and advanced AI applications across MedStar's network to enhance diagnostic precision.

In March 2026, PathAI received U.S. FDA Breakthrough Device Designation for PathAssist Derm, an AI-powered solution designed to transform dermatopathology workflows by assisting in the identification of skin cancers.

In March 2026, Hamamatsu Photonics K.K. and Sakura Finetek entered into a global alliance to integrate Hamamatsu's NanoZoomer slide scanners with Sakura's laboratory automation to streamline end-to-end pathology workflows.

Products Covered:

  • Scanners
  • Software
  • Storage and Communication Systems

Types Covered:

  • Human Pathology
  • Veterinary Pathology

Deployment Modes Covered:

  • On-Premise
  • Cloud-Based

Workflows Covered:

  • Pre-Analytical Phase
  • Analytical Phase
  • Post-Analytical Phase

Technologies Covered:

  • Digital Imaging
  • Artificial Intelligence
  • Machine Learning
  • Cloud Computing
  • Telepathology

Applications Covered:

  • Disease Diagnosis
  • Drug Discovery and Development
  • Teleconsultation
  • Academic Research
  • Training and Education

End Users Covered:

  • Hospitals
  • Diagnostic Laboratories
  • Pharmaceutical and Biotechnology Companies
  • Academic and Research Institutes

Regions Covered:

  • North America
    • United States
    • Canada
    • Mexico
  • Europe
    • United Kingdom
    • Germany
    • France
    • Italy
    • Spain
    • Netherlands
    • Belgium
    • Sweden
    • Switzerland
    • Poland
    • Rest of Europe
  • Asia Pacific
    • China
    • Japan
    • India
    • South Korea
    • Australia
    • Indonesia
    • Thailand
    • Malaysia
    • Singapore
    • Vietnam
    • Rest of Asia Pacific
  • South America
    • Brazil
    • Argentina
    • Colombia
    • Chile
    • Peru
    • Rest of South America
  • Rest of the World (RoW)
    • Middle East
  • Saudi Arabia
  • United Arab Emirates
  • Qatar
  • Israel
  • Rest of Middle East
    • Africa
  • South Africa
  • Egypt
  • Morocco
  • Rest of Africa

What our report offers:

  • Market share assessments for the regional and country-level segments
  • Strategic recommendations for the new entrants
  • Covers Market data for the years 2023, 2024, 2025, 2026, 2027, 2028, 2030, 2032 and 2034
  • Market Trends (Drivers, Constraints, Opportunities, Threats, Challenges, Investment Opportunities, and recommendations)
  • Strategic recommendations in key business segments based on the market estimations
  • Competitive landscaping mapping the key common trends
  • Company profiling with detailed strategies, financials, and recent developments
  • Supply chain trends mapping the latest technological advancements

Free Customization Offerings:

All the customers of this report will be entitled to receive one of the following free customization options:

  • Company Profiling
    • Comprehensive profiling of additional market players (up to 3)
    • SWOT Analysis of key players (up to 3)
  • Regional Segmentation
    • Market estimations, Forecasts and CAGR of any prominent country as per the client's interest (Note: Depends on feasibility check)
  • Competitive Benchmarking
    • Benchmarking of key players based on product portfolio, geographical presence, and strategic alliances

Table of Contents

1 Executive Summary

  • 1.1 Market Snapshot and Key Highlights
  • 1.2 Growth Drivers, Challenges, and Opportunities
  • 1.3 Competitive Landscape Overview
  • 1.4 Strategic Insights and Recommendations

2 Research Framework

  • 2.1 Study Objectives and Scope
  • 2.2 Stakeholder Analysis
  • 2.3 Research Assumptions and Limitations
  • 2.4 Research Methodology
    • 2.4.1 Data Collection (Primary and Secondary)
    • 2.4.2 Data Modeling and Estimation Techniques
    • 2.4.3 Data Validation and Triangulation
    • 2.4.4 Analytical and Forecasting Approach

3 Market Dynamics and Trend Analysis

  • 3.1 Market Definition and Structure
  • 3.2 Key Market Drivers
  • 3.3 Market Restraints and Challenges
  • 3.4 Growth Opportunities and Investment Hotspots
  • 3.5 Industry Threats and Risk Assessment
  • 3.6 Technology and Innovation Landscape
  • 3.7 Emerging and High-Growth Markets
  • 3.8 Regulatory and Policy Environment
  • 3.9 Impact of COVID-19 and Recovery Outlook

4 Competitive and Strategic Assessment

  • 4.1 Porter's Five Forces Analysis
    • 4.1.1 Supplier Bargaining Power
    • 4.1.2 Buyer Bargaining Power
    • 4.1.3 Threat of Substitutes
    • 4.1.4 Threat of New Entrants
    • 4.1.5 Competitive Rivalry
  • 4.2 Market Share Analysis of Key Players
  • 4.3 Product Benchmarking and Performance Comparison

5 Global Digital Pathology Market, By Product

  • 5.1 Scanners
    • 5.1.1 Whole Slide Imaging Scanners
    • 5.1.2 High-throughput Scanners
    • 5.1.3 Low-throughput Scanners
  • 5.2 Software
    • 5.2.1 Image Management Software
    • 5.2.2 Image Analysis Software
  • 5.3 Storage and Communication Systems
    • 5.3.1 Data Storage Solutions
    • 5.3.2 Networking and Communication Platforms

6 Global Digital Pathology Market, By Type

  • 6.1 Human Pathology
  • 6.2 Veterinary Pathology

7 Global Digital Pathology Market, By Deployment Mode

  • 7.1 On-Premise
  • 7.2 Cloud-Based

8 Global Digital Pathology Market, By Workflow

  • 8.1 Pre-Analytical Phase
  • 8.2 Analytical Phase
    • 8.2.1 Slide Digitization
    • 8.2.2 Image Processing
  • 8.3 Post-Analytical Phase
    • 8.3.1 Image Management
    • 8.3.2 Data Storage and Retrieval
    • 8.3.3 Reporting and Collaboration

9 Global Digital Pathology Market, By Technology

  • 9.1 Digital Imaging
  • 9.2 Artificial Intelligence
  • 9.3 Machine Learning
  • 9.4 Cloud Computing
  • 9.5 Telepathology

10 Global Digital Pathology Market, By Application

  • 10.1 Disease Diagnosis
  • 10.2 Drug Discovery and Development
  • 10.3 Teleconsultation
  • 10.4 Academic Research
  • 10.5 Training and Education

11 Global Digital Pathology Market, By End User

  • 11.1 Hospitals
  • 11.2 Diagnostic Laboratories
  • 11.3 Pharmaceutical and Biotechnology Companies
  • 11.4 Academic and Research Institutes

12 Global Digital Pathology Market, By Geography

  • 12.1 North America
    • 12.1.1 United States
    • 12.1.2 Canada
    • 12.1.3 Mexico
  • 12.2 Europe
    • 12.2.1 United Kingdom
    • 12.2.2 Germany
    • 12.2.3 France
    • 12.2.4 Italy
    • 12.2.5 Spain
    • 12.2.6 Netherlands
    • 12.2.7 Belgium
    • 12.2.8 Sweden
    • 12.2.9 Switzerland
    • 12.2.10 Poland
    • 12.2.11 Rest of Europe
  • 12.3 Asia Pacific
    • 12.3.1 China
    • 12.3.2 Japan
    • 12.3.3 India
    • 12.3.4 South Korea
    • 12.3.5 Australia
    • 12.3.6 Indonesia
    • 12.3.7 Thailand
    • 12.3.8 Malaysia
    • 12.3.9 Singapore
    • 12.3.10 Vietnam
    • 12.3.11 Rest of Asia Pacific
  • 12.4 South America
    • 12.4.1 Brazil
    • 12.4.2 Argentina
    • 12.4.3 Colombia
    • 12.4.4 Chile
    • 12.4.5 Peru
    • 12.4.6 Rest of South America
  • 12.5 Rest of the World (RoW)
    • 12.5.1 Middle East
      • 12.5.1.1 Saudi Arabia
      • 12.5.1.2 United Arab Emirates
      • 12.5.1.3 Qatar
      • 12.5.1.4 Israel
      • 12.5.1.5 Rest of Middle East
    • 12.5.2 Africa
      • 12.5.2.1 South Africa
      • 12.5.2.2 Egypt
      • 12.5.2.3 Morocco
      • 12.5.2.4 Rest of Africa

13 Strategic Market Intelligence

  • 13.1 Industry Value Network and Supply Chain Assessment
  • 13.2 White-Space and Opportunity Mapping
  • 13.3 Product Evolution and Market Life Cycle Analysis
  • 13.4 Channel, Distributor, and Go-to-Market Assessment

14 Industry Developments and Strategic Initiatives

  • 14.1 Mergers and Acquisitions
  • 14.2 Partnerships, Alliances, and Joint Ventures
  • 14.3 New Product Launches and Certifications
  • 14.4 Capacity Expansion and Investments
  • 14.5 Other Strategic Initiatives

15 Company Profiles

  • 15.1 F. Hoffmann-La Roche Ltd.
  • 15.2 Danaher Corporation
  • 15.3 Koninklijke Philips N.V.
  • 15.4 Leica Biosystems Nussloch GmbH
  • 15.5 Hamamatsu Photonics K.K.
  • 15.6 3DHISTECH Ltd.
  • 15.7 Visiopharm A/S
  • 15.8 Indica Labs Inc.
  • 15.9 Paige AI Inc.
  • 15.10 Proscia Inc.
  • 15.11 Sectra AB
  • 15.12 Olympus Corporation
  • 15.13 Huron Digital Pathology
  • 15.14 OptraSCAN Inc.
  • 15.15 XIFIN Inc.
  • 15.16 Inspirata Inc.
  • 15.17 Mindpeak GmbH
  • 15.18 PathAI Inc.

List of Tables

  • Table 1 Global Digital Pathology Market Outlook, By Region (2023-2034) ($MN)
  • Table 2 Global Digital Pathology Market Outlook, By Product (2023-2034) ($MN)
  • Table 3 Global Digital Pathology Market Outlook, By Scanners (2023-2034) ($MN)
  • Table 4 Global Digital Pathology Market Outlook, By Whole Slide Imaging Scanners (2023-2034) ($MN)
  • Table 5 Global Digital Pathology Market Outlook, By High-throughput Scanners (2023-2034) ($MN)
  • Table 6 Global Digital Pathology Market Outlook, By Low-throughput Scanners (2023-2034) ($MN)
  • Table 7 Global Digital Pathology Market Outlook, By Software (2023-2034) ($MN)
  • Table 8 Global Digital Pathology Market Outlook, By Image Management Software (2023-2034) ($MN)
  • Table 9 Global Digital Pathology Market Outlook, By Image Analysis Software (2023-2034) ($MN)
  • Table 10 Global Digital Pathology Market Outlook, By Storage and Communication Systems (2023-2034) ($MN)
  • Table 11 Global Digital Pathology Market Outlook, By Data Storage Solutions (2023-2034) ($MN)
  • Table 12 Global Digital Pathology Market Outlook, By Networking and Communication Platforms (2023-2034) ($MN)
  • Table 13 Global Digital Pathology Market Outlook, By Type (2023-2034) ($MN)
  • Table 14 Global Digital Pathology Market Outlook, By Human Pathology (2023-2034) ($MN)
  • Table 15 Global Digital Pathology Market Outlook, By Veterinary Pathology (2023-2034) ($MN)
  • Table 16 Global Digital Pathology Market Outlook, By Deployment Mode (2023-2034) ($MN)
  • Table 17 Global Digital Pathology Market Outlook, By On-Premise (2023-2034) ($MN)
  • Table 18 Global Digital Pathology Market Outlook, By Cloud-Based (2023-2034) ($MN)
  • Table 19 Global Digital Pathology Market Outlook, By Workflow (2023-2034) ($MN)
  • Table 20 Global Digital Pathology Market Outlook, By Pre-Analytical Phase (2023-2034) ($MN)
  • Table 21 Global Digital Pathology Market Outlook, By Analytical Phase (2023-2034) ($MN)
  • Table 22 Global Digital Pathology Market Outlook, By Slide Digitization (2023-2034) ($MN)
  • Table 23 Global Digital Pathology Market Outlook, By Image Processing (2023-2034) ($MN)
  • Table 24 Global Digital Pathology Market Outlook, By Post-Analytical Phase (2023-2034) ($MN)
  • Table 25 Global Digital Pathology Market Outlook, By Image Management (2023-2034) ($MN)
  • Table 26 Global Digital Pathology Market Outlook, By Data Storage and Retrieval (2023-2034) ($MN)
  • Table 27 Global Digital Pathology Market Outlook, By Reporting and Collaboration (2023-2034) ($MN)
  • Table 28 Global Digital Pathology Market Outlook, By Technology (2023-2034) ($MN)
  • Table 29 Global Digital Pathology Market Outlook, By Digital Imaging (2023-2034) ($MN)
  • Table 30 Global Digital Pathology Market Outlook, By Artificial Intelligence (2023-2034) ($MN)
  • Table 31 Global Digital Pathology Market Outlook, By Machine Learning (2023-2034) ($MN)
  • Table 32 Global Digital Pathology Market Outlook, By Cloud Computing (2023-2034) ($MN)
  • Table 33 Global Digital Pathology Market Outlook, By Telepathology (2023-2034) ($MN)
  • Table 34 Global Digital Pathology Market Outlook, By Application (2023-2034) ($MN)
  • Table 35 Global Digital Pathology Market Outlook, By Disease Diagnosis (2023-2034) ($MN)
  • Table 36 Global Digital Pathology Market Outlook, By Drug Discovery and Development (2023-2034) ($MN)
  • Table 37 Global Digital Pathology Market Outlook, By Teleconsultation (2023-2034) ($MN)
  • Table 38 Global Digital Pathology Market Outlook, By Academic Research (2023-2034) ($MN)
  • Table 39 Global Digital Pathology Market Outlook, By Training and Education (2023-2034) ($MN)
  • Table 40 Global Digital Pathology Market Outlook, By End User (2023-2034) ($MN)
  • Table 41 Global Digital Pathology Market Outlook, By Hospitals (2023-2034) ($MN)
  • Table 42 Global Digital Pathology Market Outlook, By Diagnostic Laboratories (2023-2034) ($MN)
  • Table 43 Global Digital Pathology Market Outlook, By Pharmaceutical and Biotechnology Companies (2023-2034) ($MN)
  • Table 44 Global Digital Pathology Market Outlook, By Academic and Research Institutes (2023-2034) ($MN)

Note: Tables for North America, Europe, APAC, South America, and Rest of the World (RoW) Regions are also represented in the same manner as above.